| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Consumer health outlet |
| Population | Women |
| Source | Healthline |
| URL | healthline.com/health-news/testosterone-prescriptions-for-women-surge-amid-pharmacy-access-barriers (opens in a new tab) |
Specific Claim Evaluated
Professional societies support testosterone for hypoactive sexual desire disorder in postmenopausal women but not for other menopause symptoms, and testosterone declines with aging rather than specifically at menopause.
Primary Research Supporting or Contradicting the Claim
The consensus statement restricts the evidence-based indication to hypoactive sexual desire disorder and finds insufficient data for other symptoms (Davis et al., 2019). Testosterone declined with age and did not differ by menopausal stage (Wang et al., 2025).
Corrected Evidence-Based Interpretation
Accurate.
Rationale for Grade
The article reports the position of The Menopause Society correctly and includes an expert explanation that matches population data on testosterone by menopausal stage. The editorial process (named author and fact checker) is disclosed. No unsupported benefit claims are made.
References
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD." - Wang Y, Islam RM, Bond M, Davis SR. Testosterone and pre-androgens by age and menopausal stage at midlife: findings from a cross-sectional study. EBioMedicine. 2025;121:105972. PMID
Supporting excerpt: "These data do not support menopause per se as an indication for testosterone supplementation."